PERSIST-2 phase 3 study of pacritinib shows encouraging clinical activity
CTI BioPharma announced data from PERSIST-2, a randomized Phase 3 clinical trial comparing pacritinib with physician-specified best available therapy, for treatment of high risk, thrombocytopenic myelofibrosis patients. Pacritinib is an investigational oral multikinase inhibitor. December 06, 2016